“It was pretty clear as we looked at pharmacy-cost trends that where we were and where we were trying to go was just unsustainable,” Paul Markovich, CEO of Blue Shield of California explains to Bloomberg Intelligence. Markovich joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the details of the company’s new prescription model, why it’s walking away from traditional pharmacy-benefit managers arrangements and how the insurer is going to generate $500 million in savings on over $4 billion in annual drug spending. Blue Shield’s work-around digital innovation, value-based care and the potential of GLP-1 drugs are also highlighted.

“It was pretty clear as we looked at pharmacy-cost trends that where we were and where we were trying to go was just unsustainable,” Paul Markovich, CEO of Blue Shield of California explains to Bloomberg Intelligence. Markovich joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the details of the company’s new prescription model, why it’s walking away from traditional pharmacy-benefit managers arrangements and how the insurer is going to generate $500 million in savings on over $4 billion in annual drug spending. Blue Shield’s work-around digital innovation, value-based care and the potential of GLP-1 drugs are also highlighted.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Blue Shield of California Tackling Pharmacy Care with a New Model

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/cdb50e38-8ca1-48fd-be85-b0b4015049d7/transcript

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.

&ldquo;In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,&rdquo; says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire&rsquo;s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women&rsquo;s health, the evolving AI landscape and the personal values &mdash; integrity, work ethic and mission &mdash; that shape how she invests and leads.

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/11341ee2-b121-40cd-858d-b41200952d3e/transcript

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing “high-hanging fruit,” the hard-to-drug targets others can’t reach, and what it will take to reverse Eroom’s Law.

&ldquo;Nothing excites me as much as the potential for AI,&rdquo; Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&amp;D leader, explains why today&rsquo;s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing &ldquo;high-hanging fruit,&rdquo; the hard-to-drug targets others can&rsquo;t reach, and what it will take to reverse Eroom&rsquo;s Law.

Xaira’s War on Trial-and-Error Drug Development

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e37a2db7-b788-4227-92c6-b40a00fd1db4/transcript

“IVL in general is an enabler for physicians to do very complex procedures — it’s simple, it’s easy to use and it’s safe. So even a physician that doesn’t have a lot of experience doing complex cases can now treat patients that they previously weren’t treating,” AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.

&ldquo;IVL in general is an enabler for physicians to do very complex procedures &mdash; it&rsquo;s simple, it&rsquo;s easy to use and it&rsquo;s safe. So even a physician that doesn&rsquo;t have a lot of experience doing complex cases can now treat patients that they previously weren&rsquo;t treating,&rdquo; AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.

AVS’ Toland on Next Lithotripsy Launch

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/91509729-b58e-4a94-aacc-b40400e06835/transcript

Blue Shield of California Tackling Pharmacy Care with a New Model

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips